MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Design Therapeutics Inc

Abrir

6.59 2.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

6.34

Máximo

6.82

Indicadores-chave

By Trading Economics

Rendimento

-1.4M

-19M

Margem de lucro

-2,321.599

Funcionários

57

EBITDA

-1.3M

-22M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-22.96% downside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

137M

362M

Abertura anterior

3.94

Fecho anterior

6.59

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Design Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2025, 16:58 UTC

Ganhos

BMW Trims 2025 View, Citing Weaker Performance in China

7 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 de out. de 2025, 23:19 UTC

Conversa de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 de out. de 2025, 22:40 UTC

Conversa de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 20:44 UTC

Ações em Alta

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 de out. de 2025, 19:42 UTC

Conversa de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 de out. de 2025, 19:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 de out. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 de out. de 2025, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 de out. de 2025, 15:33 UTC

Conversa de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 de out. de 2025, 15:25 UTC

Conversa de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 de out. de 2025, 15:15 UTC

Conversa de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 de out. de 2025, 14:52 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Design Therapeutics Inc Previsão

Preço-alvo

By TipRanks

-22.96% parte inferior

Previsão para 12 meses

Média 5 USD  -22.96%

Máximo 5 USD

Mínimo 5 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Design Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

2 ratings

0

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.26 / 3.63Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat